Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06546488 · ClinicalTrials.gov registry record
Cognitive Assessment Tools for Huntington's Disease.
A clinical trial of Huntington Disease, sponsored by Ohio State University.
- Recruiting
- Registry status
- 76
- Enrollment target
- 1
- Study location
NCT06546488 is a study of Huntington Disease that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 76 participants, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06546488, a study of Huntington Disease, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
Conditions Studied
Interventions
- BEHAVIORAL Assessments
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2027-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06546488
The ClinicalTrials.gov registry entry for NCT06546488 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (88% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Assessments is the first listed.
NCT06546488 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06546488 about?
NCT06546488 is a clinical study titled "Cognitive Assessment Tools for Huntington's Disease.". The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is...
What is the current status of trial NCT06546488?
This trial is currently recruiting. The enrollment target is 76 participants. The study started on 2025-06-20. Estimated completion is 2027-12-01.
What conditions does trial NCT06546488 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT06546488?
The interventions under investigation include: Assessments (BEHAVIORAL).
Who is sponsoring clinical trial NCT06546488?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06546488 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.